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Abstract
Background: Epigenetic changes (i.e., chromatin modifications) occur during chondrogenesis and in osteoarthritis
(OA). We investigated the effect of H3K27me3 demethylase inhibition on chondrogenesis and assessed its utility in
cartilage tissue engineering and in understanding cartilage destruction in OA.
Methods: We used a high-content screen to assess the effect of epigenetic modifying compounds on collagen
output during chondrogenesis of monolayer human mesenchymal stem cells (MSCs). The impact of GSK-J4 on
gene expression, glycosaminoglycan output and collagen formation during differentiation of MSCs into cartilage
discs was investigated. Expression of lysine (K)-specific demethylase 6A (UTX) and Jumonji domain-containing 3
(JMJD3), the HEK27Me3 demethylases targeted by GSK-J4, was measured in damaged and undamaged cartilage
from patients with OA. The impact of GSK-J4 on ex vivo cartilage destruction and expression of OA-related genes
in human articular chondrocytes (HACs) was assessed. H3K27Me3 demethylase regulation of transforming growth
factor (TGF)-β-induced gene expression was measured in MSCs and HACs.
Results: Treatment of chondrogenic MSCs with the H3K27me3 demethylase inhibitor GSK-J4, which targets JMJD3
and UTX, inhibited collagen output; expression of chondrogenic genes, including SOX9 and COL2A1; and disrupted
glycosaminoglycan and collagen synthesis. JMJD3 but not UTX expression was increased during chondrogenesis
and in damaged OA cartilage, suggesting a predominant role of JMJD3 in chondrogenesis and OA. GSK-J4
prevented ex vivo cartilage destruction and expression of the OA-related genes MMP13 and PTGS2. TGF-β is a key
regulator of chondrogenesis and articular cartilage homeostasis, and TGF-β-induced gene expression was inhibited
by GSK-J4 treatment of both chondrogenic MSCs and HACs.
Conclusions: Overall, we show that H3K27me3 demethylases modulate chondrogenesis and that enhancing this
activity may improve production of tissue-engineered cartilage. In contrast, targeted inhibition of H3K27me3
demethylases could provide a novel approach in OA therapeutics.
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Background
Osteoarthritis (OA) is the most common of the arthriti-
des and is characterized by loss of articular cartilage.
Treatments for OA are limited to pain relief, physiother-
apy and joint replacement surgery for end-stage disease.
To successfully treat cartilage lesions and OA, it is
paramount to improve production of tissue-engineered
cartilage and to identify disease-modifying therapeutics
that can prevent or limit cartilage degradation.
Gene expression and cellular phenotype changes
associated with OA and chondrogenesis are increasingly
being attributed to altered activity of epigenetic modify-
ing enzymes and consequent epigenetic regulation of
target genes [1, 2]. Commonly, epigenetic modifications
occur in gene promoters and include regulation of chro-
matin structure through cytosine methylation of DNA
or through modifications such as acetylation and methy-
lation of lysine residues in histone tails. Pharmacological
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intervention points in oncology have been identified by
targeting of “readers, writers and erasers” of an “epigenetic
code” [3], an avenue with largely unexplored potential in
inflammatory and degenerative diseases.
Correct regulation of transforming growth factor
(TGF)-β signalling is essential for cartilage development
[4]. Dysregulation of TGF-β pathway components leads
to impaired skeletogenesis, increased chondrocyte hyper-
trophy and an OA-like phenotype in murine models
[5, 6]. Furthermore a disrupted TGF-β signalling re-
sponse in both murine and human OA has been reported
[7]. Epigenetic regulation of the TGF-β pathway in fibrosis
has been reported, and TGF-β itself regulates expression
of epigenetic modifying enzymes [8].
We reasoned that specific targeting of epigenetic
modifying enzymes could provide valuable insight into
the role of epigenetics in chondrogenesis and OA and
help identify exploitable targets for therapeutic develop-
ment. In this work, we identified and investigated the
H3K27me3 demethylases as novel targets in cartilage
tissue engineering and OA pathogenesis.
Methods
Cell culture and tissue preparation
Primary human bone marrow-derived mesenchymal stem
cells (MSCs) were purchased from Lonza (Walkersville,
MD, USA) and cultured in MSC expansion media consist-
ing of MesenPRO RS basal media with MesenPRO RS
supplement, 2 mML-glutamine, 100 IU ml−1 penicillin
and 100 mg ml−1 streptomycin (Life Technologies,
Carlsbad, CA, USA). MSCs were used for all experi-
ments before passage 7.
Human articular cartilage for gene expression analysis
was from damaged and undamaged regions of the med-
ial tibial plateau of individuals undergoing unicompart-
mental knee replacement for anteromedial OA (n = 5
patients). For cell culture, cartilage from the medial tibial
plateau of patients undergoing unicompartmental knee
replacement for OA was dissected and digested over-
night with collagenase. HACs were cultured in basal
medium composed of high-glucose DMEM (Lonza) con-
taining 2 mM glutamine and 100 IU ml−1 penicillin and
100 mg ml−1 streptomycin (Life Technologies).
Ethical approval was granted (09/H0606/11) by the
local research ethics committee (Oxford Research Ethics
Committee B) for all work on human articular cartilage
and chondrocytes, and informed consent was obtained
from all patients.
Chondrogenic differentiation
For monolayer chondrogenesis, MSCs in expansion
media were seeded at 20,000 cells/well in a 96-well plate
and left to adhere overnight. Expansion media were re-
placed with high-glucose DMEM (Lonza), chondrogenic
differentiation media containing 100 μg/ml sodium
pyruvate (Lonza), 10 ng/ml TGF-β3 (R&D Systems,
Minneapolis, MN, USA), 100 nM dexamethasone, 1×
ITS+ premix (BD Biosciences, San Jose, CA, USA),
40 μg/ml proline, and 25 μg/ml ascorbate 2-phosphate
(Sigma-Aldrich, St. Louis, MO, USA). Media were
refreshed every 2–3 days.
For cartilage disc generation, MSCs were resus-
pended in chondrogenic medium and 100 μl of MSCs
at 5 × 106 cells/ml were pipetted onto 6.5-mm, 0.8-μm
pore polycarbonate Transwell filters (Corning Costar,
Corning, NY, USA) in a 24-well plate, centrifuged
(200 × g, 5 min) before addition of 500 μl of chon-
drogenic medium to the lower well. Media were
refreshed every 2–3 days.
Compound screen
Using a focused library of 31 small-molecule inhibitors
against various readers, writers and erasers of chromatin
modifications, we assessed chondrogenic differentiation
of MSCs. Chondrogenic monolayer MSCs were incu-
bated for 7 days in the presence or absence of epigenetic
modifying compounds, where compounds and media
were refreshed every 2–3 days. Cell viability was
assessed using the alamarBlue assay (Life Technolo-
gies) before fixing cells in 4 % formaldehyde and
staining with 10 μg/ml Nile Red, which binds non-
specifically to collagens and lipids and allows visualization
of chondrogenic nodules [9]. Nile Red staining intensity
was assessed using excitation at 485 nm in the BD Path-
way (BD Biosciences). Data are presented as Nile Red in-
corporation relative to cell viability (Additional file 1:
Figure S1).
Cytokine and GSK-J4 treatments
Primary HACs were seeded at 6000 cells/well in a 96-
well plate and allowed to adhere overnight. HACs were
treated with GSK-J4 (10 μM), interleukin (IL)-1β (5 ng/
ml), IL-6 (10 ng/ml), oncostatin M (OSM) (10 ng/ml),
TGF-β (4 ng/ml) or TGF-β and GSK-J4. Dimethyl
sulphoxide (DMSO) alone was added to all wells not
containing GSK-J4. MSCs were seeded at 20,000 cells/
well of a 96-well plate and allowed to adhere overnight
in MSC expansion medium before 1- and 24-h treat-
ment in basal, chondrogenic (plus DMSO carrier) and
chondrogenic medium plus GSK-J4. Treated HACs and
MSCs were washed twice in PBS, and cells were
harvested in cells to complementary DNA (cDNA) lysis
buffer (Ambion; Thermo Fisher Scientific, Austin, TX,
USA) prior to cDNA synthesis. GSK-J5 (10 μM), the less
active enantiomer of GSK-J4, was used as an additional
comparator for experiments (Additional file 1: Figure S1
and Additional file 2: Figure S3).
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Small interfering RNA
HACs and MSCs were transfected with 5 nM (final con-
centration) of small interfering (siRNA) against Jumonji
domain-containing 3 (JMJD3) and lysine (K)-specific
demethylase 6A (UTX) (QIAGEN, Hilden, Germany) or
AllStars non-targeting negative control (QIAGEN) using
DharmaFECT reagent (GE Healthcare, Little Chalfont,
UK) according to the manufacturer’s instructions. MSCs
were pre-treated with siRNA for 48 h prior to induction
of chondrogenesis. HACs were transfected with siRNA
72 h prior to harvest for gene expression analysis.
Gene expression analysis
Following cytokine treatment of monolayer HACs and
MSCs, cell-to-cDNA lysates were treated with DNase
and synthesized with cDNA using Moloney murine
leukaemia virus (MMLV) reverse transcriptase (Life Tech-
nologies) according to the manufacturer’s instructions.
MSC cartilage discs were harvested in TRIzol reagent (Life
Technologies) and ground using disposable plastic pestles
and Molecular Grinding Resin (G-Biosciences, St. Louis,
MO, USA). Human articular cartilage was snap frozen,
crushed and ground in liquid nitrogen using a pestle and
mortar before RNA extraction using TRIzol reagent (Life
Technologies). Total RNA was converted to cDNA using
MMLV reverse transcriptase (Life Technologies) accord-
ing to the manufacturer’s instructions.
Expression of genes of interest was measured by quanti-
tative reverse transcription polymerase chain reaction
(RT-qPCR) on an Applied Biosystems ViiA 7 system using
SYBR Green (Life Technologies). Relative quantification is
expressed as the comparative cycle threshold (2−ΔCt),
where ΔCt is Ct(gene of interest) −Ct(reference gene TBP
or GAPDH). Samples where the reference gene Ct was
greater than ±1.5 Ct from the median were excluded from
further analyses.
Immunocytochemistry
MSCs and HACs were seeded in chamber slides and
allowed to adhere overnight. MSCs were treated with con-
trol medium (DMSO alone) or chondrogenic medium
with or without GSK-J4 (10 μM). HACs were treated with
control medium (DMSO alone) or TGF-β with or without
GSK-J4. After 24-h (MSCs) and 6-h treatment (HAC),
cells were fixed in 4 % formaldehyde and stained overnight
at 4 °C with anti-H3K27Me3 (5 μg/ml, catalog number
ab6002; Abcam, Cambridge, UK) before 1-h incubation at
room temperature with rabbit antimouse immunoglobulin
G. Nuclei were visualized using 4′,6-diamidino-2-pheny-
lindole stain, and the cell cytoskeleton was visualized with
Texas Red-conjugated phalloidin (Life Technologies).
Images were obtained using a Zeiss inverted micro-
scope using AxioVision software (Carl Zeiss Microscopy,
Thornwood, NY, USA).
Dimethylmethylene blue assay for glycosaminoglycan
content
Primary human articular cartilage explants were incu-
bated with 5 ng/ml IL-1 and 10 ng/ml OSM in the pres-
ence or absence of GSK-J4 (10 μM) for 7 days, and
media were collected and harvested every 2–3 days.
Cartilage explants at day 7 and MSC cartilage discs at
14 days of differentiation were digested with papain
overnight. Aliquots of media and digested cartilage were
mixed with 1,9-dimethylmethylene blue and immediately
read at 630 nm (SpectraMax Plus 384; Molecular Devices,
Sunnyvale, CA, USA).
Second harmonic generation
Z-stack images were acquired on a Zeiss LSM 710 NLO
confocal scanning microscope (Carl Zeiss Microscopy)
coupled to a Chameleon Vision II multiphoton laser
(Coherent, Santa Clara, CA, USA) tuned to 900 nm.
Second harmonic generation (SHG) was confirmed at
precisely 450 nm using a spectral detector and detected
between 370 and 480 nm using non-descanned detectors
through a × 25, 0.8 numerical aperture glycerol immersion
objective. The stack thickness was 80–100 μm with a step
size of 1.39 μm.
Statistical analysis
Analyses were carried out using Prism 6.0 software
(GraphPad, La Jolla, CA, USA). Student’s t test was used
to test differences between two samples. Analysis of vari-
ance with Dunnett’s post-test was used for multiple com-
parisons. p < 0.05 was considered statistically significant.
Results
Using a focused library of 31 epigenetic inhibitors in
chondrogenesis of human MSCs (Fig. 1), we identified
and confirmed the molecule GSK-J4 as an inhibitor of
collagen output (0.63-fold; p = 0.0079) (Fig. 2a). No im-
pact of GSK-J4 treatment on cell viability was detected
(data not shown). GSK-J4 inhibits the KDM6 family of
H3K27me3 demethylases JMJD3 and UTX. GSK-J4
has also been shown to target the KDM5 family of
H3K4me3 demethylases [10].
Histone arginine or lysine residues can be mono-, di-
or trimethylated. Histone 3 lysine 27 trimethylation
(H3K27me3) is associated with inactive gene promoters,
leading to Polycomb-mediated repression. The JMJD3
and UTX demethylases target these trimethyl groups
and overcome this repression [11]. Accordingly, inhib-
ition of UTX and JMJD3 by GSK-J4 maintains
H3K27me3-driven repression of gene expression.
JMJD3 regulates chondrogenesis
JMJD3 but not UTX expression was increased at day 4
(3.0-fold, p = 0.017)), day 7 (2.9-fold, p = 0.014) and day
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14 (2.6-fold, p = 0.0327) of chondrogenic differentiation
of MSCs into cartilage discs (Fig. 2b). Consequently, the
inhibition of JMJD3 and UTX activity was further ex-
plored by assessing the expression of chondrogenic
markers in MSC-generated cartilage discs.
At days 7 and 14 of chondrogenic differentiation, in-
hibition of H3K27me3 demethylases led to a reduction
in expression of SRY (sex determining region Y)-box 9
(SOX9) (0.39-fold, p < 0.0001; 0.64-fold, p = 0.0019); col-
lagen type II, alpha 1 (COL2A1) (0.08-fold, p < 0.0001;
0.67-fold, p = 0.0476); and collagen type X, alpha 1
(COL10A1) (0.36-fold, p < 0.0001; 0.50-fold, p = 0.0002).
Aggrecan (ACAN) expression was reduced at day 7
(0.23-fold, p < 0.0001) and collagen type I, alpha 1
(COL1A1) expression was increased at days 7 and 14
(1.64-fold, p < 0.0001; 2.43-fold, p = 0.0019) (Fig. 2c–g).
To test whether these effects were mediated by JMJD3
and UTX, MSCs were treated with siRNA against JMJD3
and UTX prior to Transwell induction of chondrogene-
sis. Expression of ACAN, COL2A1, COL10A1 and SOX9
was decreased, whilst expression of COL1A1 was not
altered (Fig. 2h and Additional file 3: Figure S2 show
siRNA validation and treatment of MSCs with an add-
itional siRNA against JMJD3 and UTX). Expression of
adipogenic and osteogenic genes was not effected by
GSK-J4 during chondrogenesis (data not shown). The
glycosaminoglycan (GAG) content of cartilage discs was
also reduced when GSK-J4 was present in chondrogenic
medium (0.83-fold, p = 0.041) (Fig. 2i). SHG was used to
visualize collagen fibre organization after 14 days of
chondrogenic differentiation (Fig. 3). In the presence of
GSK-J4, fibres were disordered and appeared thicker and
more sparsely distributed.
We also assessed whether inhibition of H3K27me3
demethylases by GSK-J4 regulated initiation of chondro-
genesis and reversion of MSCs to a less stem cell-like
phenotype by assessing expression of the MSC-related
gene NANOG. Induction of chondrogenesis caused a re-
duction in NANOG expression that was inhibited in the
presence of GSK-J4 (4.0-fold, p = 0.0023) (Fig. 4a). TGF-β
initiated MSC condensation and production of healthy
cartilage, and expression of the TGF-β target gene PAI1
by chondrogenic MSCs was inhibited by GSK-J4. Interest-
ingly, JMJD3 expression was also induced by TGF-β1 and
inhibited in the presence of GSK-J4 (Fig. 4b).
To confirm that H3K27me3 levels are regulated in
chondrogenesis, we stained chondrogenic MSCs for tri-
methylated H3K27. MSCs stimulated with chondrogenic
medium (containing TGF-β to initiate and drive chon-
drogenesis) showed a reduction in H3K27me3 staining
relative to control basal medium (Fig. 4c). Inhibition of
JMJD3 and UTX by addition of GSK-J4 to chondrogenic
medium inhibited this reduction in H3K27me3 staining.
OA is postulated to result from reversion of chondro-
cytes to a more developmental phenotype [12]; thus, we
assessed whether there was a role for JMJD3 and UTX
in OA. Expression of JMJD3 (2.16-fold, p = 0.007) (Fig. 5a)
but not UTX was increased in damaged cartilage
compared with undamaged cartilage from the tibial plat-
eau of the OA knee. GSK-J4 treatment caused a decrease
in gene expression of OA-associated matrix metallopepti-
dase 13 (MMP13) (0.43-fold, p = 0.0032), prostaglandin-
Fig. 1 Screen of epigenetic modifying compounds in chondrogenesis. Mesenchymal stem cells were cultured with epigenetic modifying
compounds for 7 days in control and chondrogenic media. Collagen output was assessed via Nile Red incorporation and normalized to viable
cells using the alamarBlue assay. DMSO dimethyl sulphoxide
Yapp et al. Arthritis Research & Therapy  (2016) 18:158 Page 4 of 10
endoperoxide synthase 2 (PTGS2) (0.49-fold, p = 0.0480)
and COL10A1 (0.40-fold, p = 0.0023) (Fig. 5b). Expression
of MMP13, PTGS2 and COL10A1 was decreased follow-
ing treatment of HACs with siRNA against JMJD3, but
there was no significant decrease in expression of these
genes following knockdown of UTX. (Fig. 5c and
Additional file 4: Figure S4 show siRNA validation and
gene expression in HACs following treatment with an
additional siRNA against JMJD3 and UTX.) GSK-J4
inhibited IL-1β/OSM-induced GAG release from human
articular cartilage explants (0.73-fold, p = 0.0015) (Fig. 5d),
while there was no effect of GSK-J4 alone.
Fig. 3 The impact of trimethylated histone 3 lysine 27 (H3K27me3) inhibition on collagen organization. Collagen organization, as assessed using
second harmonic generation, was also disordered in discs generated in the presence of GSK-J4
Fig. 2 The impact of trimethylated histone 3 lysine 27 (H3K27me3) inhibition on extracellular matrix production and chondrogenic gene expression.
a Addition of GSK-J4 to chondrogenic media of human mesenchymal stem cells (MSCs) caused a reduction in collagen production as measured by
Nile Red incorporation relative to viable cells (day 7, n = 3 individuals, 3 technical replicates per condition). b Jumonji domain-containing 3 (JMJD3)
expression was increased during chondrogenic differentiation of MSCs to form cartilage discs. Assessment of gene expression at days 7 and 14 of
chondrogenesis revealed that H3K27me3 inhibition through GSK-J4 addition to chondrogenic media resulted decreased expression of SRY (sex
determining region Y)-box 9 (SOX9), collagen type II, alpha 1 (COL2A1), aggrecan (ACAN) and collagen type X, alpha 1 (COL10A1) (c,d,f,g) and increased
expression of collagen type I, alpha 1 (COL1A1) (e) (n= 3 individuals). h MSCs were pre-treated with small interfering RNA (siRNA) against JMJD3, lysine
(K)-specific demethylase 6A (UTX) or non-targeting siRNA control prior to chondrogenic induction in Transwell culture. RNA was extracted and cDNA
synthesized at day 7 of chondrogenesis, and expression of SOX9, ACAN COL2A1, COL10A1 and COL1A1 was assessed by quantitative reverse transcription
polymerase chain reaction (n= 4 patients, n= 2 technical replicates per patient). Dashed line represents expression level following MSC treatment with
non-targeting siRNA control. i Proteoglycan content at day 14 in cartilage discs generated in Transwell cultures was reduced following addition of GSK-J4
to chondrogenic medium (n= 3 individuals). *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, ****p≤ 0.0001. Data are presented as individual data points for biological
replicates showing mean ± 95 % CI. a and i t test, b–h analysis of variance with Dunnett’s correction for multiple comparisons
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To explore the factors driving JMJD3 upregulation
in damaged OA cartilage, we treated HACs with OA-
relevant cytokines. The inflammatory cytokines IL-1β/
OSM, which also induce MMP-13 expression, caused
a significant increase in JMJD3 expression (7.56-fold,
p = 0.0085), as did TGF-β1 (12.97-fold, p < 0.0001)
(Fig. 5e).
Given the upregulation of JMJD3 by TGF-β in
HACs and the inhibition of TGF-β-driven chondro-
genesis and gene expression in MSCs, we postulated
that H3K27me3 status may impact the expression of
TGF-β target genes in HACs. In the presence of
GSK-J4, there was a significant decrease in TGF-β-
induced expression of PAI1I (0.68-fold, p = 0.0006),
JMJD3 (0.52-fold, p = 0.0011) and MMP13 (0.42-fold,
p = 0.0023) (Fig. 5f ). Treatment of HACs with TGF-β
reduced H3K27me3 staining, and this TGF-β-induced
reduction was inhibited in the presence of GSK-J4
(Fig. 6).
Discussion
In this study, we identified the H3K27me3 demethylases
as key mediators of both chondrogenesis and OA
pathogenesis. We show that inhibition of H3K27me3
demethylase activity by GSK-J4 disrupts in vitro chon-
drogenic differentiation of human MSCs but inhibits
adult human articular cartilage degradation. GSK-J4
inhibited TGF-β-induced gene expression in both MSCs
and HACs, implicating H3K27me3 demethylases in TGF-
β-led regulation of chondrogenesis and OA. H3K27me3
manipulation may thus improve outcomes in cartilage
tissue repair and might be a possible target for OA
therapeutics.
Histone arginine or lysine residues can be mono-, di-
or trimethylated. H3K27me3 is associated with inactive
gene promoters, leading to Polycomb-mediated repres-
sion. The JMJD3 and UTX demethylases specifically tar-
get these trimethyl groups and overcome this repression
of key transcription factors during differentiation [11].
Fig. 4 Impact of trimethylated histone 3 lysine 27 (H3K27me3) demethylase inhibition on mesenchymal stem cell (MSC) behaviour. a NANOG
expression in monolayer MSCs treated for 24 h with GSK-J4 and chondrogenic medium compared with chondrogenic medium alone (n = 4 individuals,
4 technical replicates per condition). b PAI1 and JMJD3 expression were decreased in monolayer MSCs treated for 1 h with GSK-J4 and chondrogenic
medium compared with chondrogenic medium alone (n = 4 individuals, 4 technical replicates per condition). c H3K27me3 staining (green) in MSCs
cultured for 24 h in control medium, chondrogenic medium or chondrogenic medium plus GSK-J4. Cell cytoskeleton/actin (phalloidin, red) and nuclear
(4′,6-diamidino-2-phenylindole, blue) staining. **p≤ 0.01, ***p≤ 0.001. Data are presented as individual data points for biological replicates showing
mean ± 95 % CI. a and b Analysis of variance with Dunnett’s correction for multiple comparisons
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Fig. 5 Regulation of global histone 3 lysine 27 trimethylation (H3K27me3) levels in osteoarthritis (OA) and adult articular cartilage. a Jumonji
domain-containing 3 (JMJD3) was increased in damaged cartilage compared with undamaged cartilage from within the same knees of patients
undergoing unicompartmental knee replacement for OA (n = 5 patients). b Inhibition of H3K27me3 demethylases by treatment of human articular
chondrocyte (HACs) with GSK-J4 for 24 h caused a decrease in matrix metallopeptidase 13 (MMP13), prostaglandin-endoperoxide synthase 2
(PTGS2) and collagen type X, alpha 1 (COL10A1) expression (n = 4 patients, 4 technical replicates per condition). Dashed line shows control expres-
sion of each gene. c HACs were treated for 72 h with small interfering RNA (siRNA) against JMJD3, lysine (K)-specific demethylase 6A (UTX) and
non-targeting siRNA control prior to RNA extraction and complementary DNA synthesis (n = 4 patients, n = 4 technical replicates per patient). Ex-
pression of MMP13, PTGS2 and COL10A1 was assessed by quantitative reverse transcription polymerase chain reaction. Dashed line shows expres-
sion level following treatment with non-targeting siRNA control. d Interleukin (IL)-1/oncostatin M (OSM)-induced proteoglycan loss from human
articular cartilage explants was reduced in the presence of GSK-J4 (n = 5 patients, 3 technical replicates per condition). e Treatment of HACs with
IL-1, IL-6 and transforming growth factor (TGF)-β increased JMJD3 expression. f Expression of PAI1, JMJD3 and MMP13 following 6-h treatment of
HACs with TGF-β with or without GSK-J4 (n = 4 patients, 4 technical replicates per condition). *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, ****p≤ 0.0001.
Data are presented as individual data points for biological replicates showing mean ± 95 % CI. a Paired t test, b–f Analysis of variance with Dun-
nett’s correction for multiple comparisons. GAG glycosaminoglycan
Fig. 6 The impact of transforming growth factor (TGF)-β treatment on histone 3 lysine 27 trimethylation (H3K27me3) levels in human articular
chondrocytes (HACs). H3K27me3 staining (green) in HACs following 1-h treatment with TGF-β or TGF-β plus GSK-J4. Cell cytoskeleton/actin
(phalloidin, red) and nuclear (4′,6-diamidino-2-phenylindole, blue) staining
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Accordingly, GSK-J4 inhibits UTX and JMJD3 activity
and thus maintains H3K27me3-driven repression of
gene expression.
We show that inhibition of JMJD3 and UTX by GSK-
J4 results in decreased total collagen and GAG output
during chondrogenesis, as well as a reduction in expres-
sion of cartilage-associated genes, including SOX9. Inter-
estingly, COL1A1 expression was increased following
GSK-J4 treatment, but not following targeted knock-
down of JMJD3 and UTX by siRNA. GSK-J4 mediated
inhibition of the KDM5 family of demethylases that tar-
get the H3K4me3 activating mark may explain the up-
regulation of COL1A1 following GSK-J4 treatment but
not following specific targeting of JMJD3 and UTX.
H3K4me3 and H3K27me3 sites have been identified in
collagen genes in other systems [8, 13]. The upregulation
of COL1A1 gene expression following GSK-J4 treatment,
in combination with repressed COL2A1 and COL10A1,
may reflect the sparser, thicker and more disorganized
collagen fibres visualized using SHG. Enhancing
H3K27me3 demethylase activity may therefore improve
in vitro cartilage tissue generation; this warrants further
investigation.
The regulation of JMJD3 but not UTX expression dur-
ing chondrogenesis suggests that JMJD3 plays the major
role, and individually targeting each enzyme using
siRNA showed that both regulated chondrogenic gene
expression, although UTX knockdown had a lesser ef-
fect. A recent study showed that JMJD3 promoted endo-
chondral bone formation in mice via association with
Runx2, and also reported that H3K27me3 levels de-
creased at the Runx2 promoter during osteogenesis [14].
In combination with our data, this suggests that JMJD3
has multiple roles in differentiation dependent upon the
context of its expression. A direct interaction of JMJD3
with SOX9, the key transcription factor in regulating
chondrogenesis, has not been reported. However, JMJD3
potentially has both direct and indirect effects on SOX9
expression. First, H3K27me3 is present within the SOX9
promoter in the limb bud mesenchyme and in OA cartil-
age [1, 15], and SOX9, amongst other chondrogenic
marker genes, including collagens, has previously been
shown to contain H3K27m e3 sites that undergo de-
methylation during chondrogenesis of human MSCs
[16]. Therefore, demethylase activity can directly control
SOX9 expression. Indirectly, demethylation of
H3K27me3 at promoter sites of accessory factors such
as the N2RF1 gene can also lead to increased SOX9 ex-
pression via N2RF1 binding to the SOX9 promoter [17].
To our knowledge, our present study is the first to
show H3K27me3 regulation in OA, and the results
suggest that upregulation of H3K27me3 demethylase
activity may promote OA progression. Inhibition of
H3K27me3 demethylases in adult HACs reduced
expression of OA- and hypertrophy-associated MMP13,
COL10A1 and PTGS2. GAG loss from IL-1/OSM-stimu-
lated human cartilage explants was reduced when
H3K27me3 demethylase activity was inhibited. Thus, in
adult cartilage, increased JMJD3 may enhance chondro-
cyte hypertrophy and matrix destruction, leading to OA
progression. Taken together, this work suggests a protect-
ive effect of the H3K27me3 repressive mark on cartilage.
The upregulation of JMJD3 in damaged OA cartilage and
by IL-1β/OSM may help drive cartilage destruction partly
through upregulating expression of matrix-degrading
MMP13.
TGF-β-induced gene expression was inhibited in both
chondrogenic MSCs and adult HACs following GSK-J4
treatment. TGF-β is a pleiotropic cytokine that is essential
for chondrogenesis. The inhibition of chondrogenesis in
the presence of GSK-J4 may thus be mediated through its
inhibition of TGF-β signalling. In OA pathogenesis, alter-
nate TGF-β signalling pathways are activated and a dysreg-
ulated TGF-β response occurs as pathology persists [7, 18].
This dysregulation may be partially driven by direct and in-
direct effects of JMJD3, which is upregulated in damaged
OA cartilage, on H3K27me3 status of TGF-β target genes.
We also show that TGF-β increased expression of JMJD3
itself in both chondrogenic MSCs and HACs, an observa-
tion also reported during epithelial-mesenchymal transition
[19]. The H3K27me3 status and exact mechanism by which
TGF-β signalling is regulated by H3K27me3 demethylases
in chondrogenic MSCs and HACs require detailed mech-
anistic exploration both in vitro and in murine models.
GSK-J4 can target H3K4me3 demethylases of the KDM5
family as well as UTX and JMJD3. A limitation of this study
is the impact of these enzymes and sites on chondrogenesis,
and we did not assess chondrocyte activity. Targeted inhib-
ition of UTX and JMJD3 by siRNA does, however, support
the important role of H3K27me3 demethylases for in vitro
cartilage generation and in expression of OA-associated
genes, including MMP13, by HACs. Future work should
characterize H3K4me3 methylation status alongside
H3K27me3 in chondrogenesis and in OA and should target
the KDM6 and KDM5 demethylases individually.
Conclusions
In the present study, we have shown that GSK-J4 treatment
and subsequent maintenance of the H3K27me3 repressive
mark decreased total collagen and GAG output during
chondrogenesis and reduced expression of cartilage-
associated genes. Enhancing H3K27me3 demethylase activ-
ity, and thus reducing the H3K27me3 repressive mark, may
therefore improve in vitro cartilage tissue generation; this
warrants further investigation. In contrast, JMJD3 was
upregulated in damaged OA cartilage and H3K27me3
inhibition prevented ex vivo cartilage degradation and
expression of OA-related genes.
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Taken together, we provide evidence that correct regu-
lation of H3K27me3 status by demethylases in chondro-
genic precursors and chondrocytes is crucial for both
chondrogenesis and maintenance of adult articular car-
tilage. Enhancing H3K27me3 activity, especially that of
JMJD3, may improve tissue-engineered cartilage and
temporally, and anatomically targeted inhibition could
prevent cartilage damage in OA.
Additional files
Additional file 1: Figure S1. The results of treatment with GSK-5, the
less active enantiomer of GSK-4, on MSCs undergoing chondrogenesis. (A-E)
Assessment of gene expression at days 7 and 14 of MSC chondrogenesis to
articular cartilage discs revealed following GSK-J4 and GSK-J5 treatment. (F)
NANOG expression in monolayer MSCs treated for 24 h with GSK-J4 and
GSK-J5. (G) PAI1 and JMJD3 expression were decreased in monolayer MSCs
treated for 1 h with GSK-J4 and GSK-J5. (H) H3K27Me3 staining (green)
in MSCs cultured for 24 h in control, chondrongenic or chondrogenic
medium plus GSK-J4 or GSK-J5. Cell cytoskeleton/actin (phalloidin, red), nu-
clear staining (DAPI, blue). (TIFF 2818 kb)
Additional file 2: Figure S3. The results of treatment with GSK-5, the
less active enantiomer of GSK-4, on HACs. A Treatment of HAC with
GSK-J5 for 24 h. B IL1/OSM-induced proteoglycan loss from human
articular cartilage explants in the presence of GSK-J4 and GSK-J5.
C Expression of PAI1, JMJD3 and MMP13 following 6 h treatment of HAC
with TGFβ +/- GSK-J4 and GSK-J5. D H3K27me3 staining (green) in HAC
following 1 h treatment with TGFβ +/- GSK-J4 or GSK-J5. Cell cytoskeleton/
actin (phalloidin, red), nuclear staining (DAPI, blue). (TIFF 1712 kb)
Additional file 3: Figure S2. siRNA validation qPCR on MSCs and
validation chondrogenic gene expression following treatment with an
additional siRNA against JMJD3 and UTX. MSC were treated with
non-targeting siRNA control and two siRNA against JMJD3 (A) and UTX
(B) at 2.5, 5 and 10 nM for 48 h. MTC = mock transfection control
(no siRNA), NTC = no transfection control. (C) Targeting JMJD3 and UTX
with additional siRNA. MSCs were pre-treated with siRNA_2 against
JMJD3, UTX or non-targeting siRNA control prior to chondrogenic
induction in transwell culture. RNA was extracted and cDNA synthesized
at day 7 of chondrogenesis and expression of SOX9, ACAN COL2A1,
COL10A1 and COL1A1 assessed by RT-qPCR (n = 4 patients, n =2 technical
replicates per patient). Dashed line represents expression level following
MSC treatment with non-targeting siRNA control. (TIFF 372 kb)
Additional file 4: Figure S4. siRNA validation qPCR on HAC and
validation HAC gene expression following treatment with an additional
siRNA against JMJD3 and UTX. HAC were treated with non-targeting
siRNA control and two siRNA against JMJD3 (A) and UTX (B) at 2.5, 5 and
10 nM for 48 h. MTC = mock transfection control (no siRNA), NTC = no
transfection control. A MSCs were pre-treated with siRNA against JMJD3,
UTX or scrambled non-targeting control prior to chondrogenic induction
in transwell culture. RNA was extracted and cDNA synthesized at day 7 of
chondrogenesis and expression of SOX9, ACAN COL2A1, COL10A1 and
COL1A1 assessed by RT-qPCR (n = 4 patients, n = 2 technical replicates
per patient). B. HAC were treated for 72 h with siRNA_2 against JMJD3,
UTX and scrambled non-targeting siRNA control prior to RNA extraction
and cDNA synthesis (n = 4 patients, n = 4 technical replicates per patient).
Expression of MMP13, PTGS2 and COL10A1 were assessed by RT-qPCR.
Dashed line shows expression level following HAC treatment with
non-targeting siRNA control. p*≤0.05, **≤0.01, ***≤0.001, ****≤0.0001.
(TIFF 337 kb)
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